Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01381861
Other study ID # 105OC201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 2011
Est. completion date December 2013

Study information

Verified date February 2019
Source Tracon Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.


Description:

Angiogenesis plays a central role in the progression of epithelial ovarian cancer. In mouse models, VEGF-inhibitors diminish ovarian tumor growth, metastasis and malignant ascites formation. Independent Phase 2 trials have demonstrated single-agent activity for bevacizumab in recurrent ovarian cancer, and randomized controlled Phase 3 trials are ongoing in the first-line setting (GOG 0218 and ICON-7) and for recurrent disease (GOG 0213, OCEANS).

TRC105 is an antibody to CD105, an important non-VEGF angiogenic target on vascular endothelial cells. TRC105 inhibits angiogenesis, tumor growth and metastases in preclinical models. In a Phase 1 study of advanced solid tumors, TRC105 therapy caused a global reduction in angiogenic biomarkers and reduced tumor burden at doses that were well-tolerated. We hypothesize that TRC105 will have single-agent activity in recurrent ovarian cancer. By targeting a non-VEGF pathway, TRC105 has the potential to complement VEGF inhibitors which could represent a major advance in ovarian cancer therapy.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date December 2013
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

- Measurable disease per RECIST 1.1

- At least one "target lesion" per RECIST 1.1

- Patients must have GOG Performance Status of 0 or 1

- Patients must have a life expectancy of = 3 months

- Resolution of all acute toxic effects of prior therapy

- Free of active infection requiring antibiotics

- Must have had one prior platinum-based chemotherapeutic regimen for management of primary disease

- Patients could have received one additional cytotoxic regimen for management of recurrent disease

- Prior therapy directed at the malignant tumor, including hormonal and immunologic agents, must be discontinued at least three weeks prior to registration. Continuation of hormone replacement therapy is permitted.

- Adequate bone marrow function, renal function, hepatic function, neurologic function, blood coagulation parameters

- Negative serum pregnancy test and effective form of contraception for patients of childbearing potential

Exclusion Criteria:

- Previous treatment with TRC105

- Current treatment on another therapeutic clinical trial

- Receipt of an investigational agent within 28 days of starting study treatment

- Serious, non-healing wounds, ulcers, or bone fractures.

- Active bleeding or pathologic conditions that carry a high risk of bleeding

- Patients with tumor involving major vessels or transmural bowel wall involvement by tumor

- Use of thrombolytic or anticoagulant agents (except heparin to maintain i.v. catheters) within 10 days prior to the first dose of TRC105

- History of deep venous thrombosis (DVT)(except patients who have received adequate anticoagulation are eligible, and may continue on anticoagulation if appropriate)

- History of peptic ulcer disease or erosive gastritis within the past 6 months

- Known active viral or nonviral hepatitis

- History or evidence of CNS disease

- Clinically significant cardiovascular disease

- Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human, chimeric, or humanized antibodies

- Pregnant or nursing

- Under the age of 18

- Patients with or with anticipation of invasive procedures including major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to treatment with TRC105

- History of other invasive malignancies, except non-melanoma skin cancer and other cancers that have been treated with no evidence of disease within the last 3 years

- History of primary endometrial cancer diagnosed within the last 5 years, unless all of the following conditions are met: Stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other FIGO Grade 3 lesions

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last five years are excluded. Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed > 3 years prior to registration, and patient remains free of recurrent or metastatic disease

- Prior radiotherapy to any portion of the abdominal cavity or pelvis

- Patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and/or nutrition

Study Design


Intervention

Biological:
Carotuximab (TRC105)
Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama
United States MD Anderson Cancer Center Houston Texas
United States Indiana University-Bren and Melvin Simon Cancer Center Indianapolis Indiana
United States University of California, San Diego La Jolla California
United States University of Southern California Los Angeles California
United States Memorial Sloan-Kettering Cancer Center New York New York
United States Palm Beach Cancer Institute West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Tracon Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival Rate After 6 Months of Treatment on Study Number of patients ongoing within the study who have not progressed after 6 months of treatment 6 months
Primary Proportion of Patients Who Have Objective Tumor Response Proportion of patients who have objective tumor response (complete or partial) by RECIST 1.1 Every 2 cycles
Primary Adverse Events Frequency of adverse events as assessed by NCI CTCAE (Version 4.0) 28 days
Secondary CA-125 Response Rate CA-125 response rate by GCIG criteria Every 2 cycles
Secondary Serum Concentrations of TRC105 Median peak and trough concentration of TRC105 by ELISA in ug/mL Cycle 1 Day 15
Secondary TRC105 Immunogenicity TRC105 Anti-Drug Antibody (ADA) Immunogenicity by ELISA 1 year
Secondary Severity of Adverse Events Severity of adverse events by NCI CTCAE 28 days post last dose of TRC105
Secondary Overall Survival Median overall survival 2 years
See also
  Status Clinical Trial Phase
Completed NCT01442051 - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Active, not recruiting NCT03648489 - Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Phase 2
Completed NCT01031381 - Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Phase 2
Terminated NCT01202890 - Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer Phase 1
Completed NCT00561795 - Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors Phase 2
Completed NCT00301756 - Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Phase 2
Completed NCT00066456 - Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer Phase 1
Completed NCT00045682 - CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Phase 2
Withdrawn NCT04368130 - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care N/A
Terminated NCT04814875 - A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy Phase 1/Phase 2
Completed NCT00989651 - Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Recruiting NCT05537844 - Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
Terminated NCT03585764 - MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Completed NCT04088786 - Phase I Trial HIPEC With Nal-irinotecan Phase 1
Completed NCT03921658 - The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer
Withdrawn NCT00551265 - Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy N/A
Completed NCT00093626 - Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Phase 2
Completed NCT03367260 - The Treatment Preferences of Women Diagnosed With Ovarian Cancer
Recruiting NCT03983226 - Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Phase 2
Recruiting NCT03373058 - Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery Phase 3